Latham & Watkins Advises on Travere Therapeutics’ Public Offering of Common Stock

Travere Therapeutics, Inc. (Nasdaq: TVTX) has announced the pricing of an underwritten public offering of 7,812,500 shares of its common stock at a price to the public of US$16 per share. All of the shares are being sold by Travere. The gross proceeds from the offering are expected to be US$125 million, before deducting the underwriting discounts and commissions and offering expenses. The offering is expected to close on November 12, 2024, subject to customary closing conditions. In addition, Travere has granted the underwriters for the offering a 30-day option to purchase up to an additional 1,171,875 shares of its common stock at the public offering price, less the underwriting discounts and commissions.

Latham & Watkins LLP represents the underwriters in the offering with a capital markets team led by San Diego partners Matt Bush and Cheston Larson, and counsel Anthony Gostanian, with associates Julian Brody, and Samantha Wang.